Skip to main content
Premium Trial:

Request an Annual Quote

TM Bioscience Secures $14.8 Million Investment

Premium

TORONTO--TM Bioscience, a DNA products company here, has closed a private placement with aggregate gross proceeds of $14,777,000. More than 13 million special warrants were issued and sold through an underwritten private placement by Yorkton Securities for proceeds of $10,477,000. Canadian Medical Discoveries purchased the remaining special warrants for proceeds of $4.3 million. TM Biosciences des igns, develops, and commercializes DNA products for medical diagnostics, therapeutics, biochips, functional genomics, and bioinformatics.

Filed under

The Scan

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.

Rett Syndrome Mouse Model Study Points to RNA Editing Possibilities

Investigators targeted MECP2 in mutant mouse models of Rett syndrome, showing in PNAS that they could restore its expression and dial down symptoms.

Investigators Find Shared, Distinct Genetic Contributors to Childhood Hodgkin Lymphoma

An association study in JAMA Network Open uncovers risk variants within and beyond the human leukocyte antigen locus.

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.